PHILADELPHIA Hemispherx Biopharma announced Thursday that it filed a new drug application to market its treatment for chronic fatigue syndrome, the Philadelphia Business Journal reports.
The company filed the application with the Food and Drug Administration for its experimental therapeutic called Ampligen. Hemispherx’s submission to the FDA includes clinical trial data involving more than 1,200 subjects and about 90,000 dose administrations.
The company said it has been developing the drug for more than 30 years, and was considered a potential treatment for AIDS and cancer before chronic fatigue. Initially, the drug was discovered and developed at Johns Hopkins University and it was later licensed to Hemispherx.
According to the Centers for Disease Control, CFS affects more than 1 million people in the United States.